Lehto VP - Search Results

1

Mesoporous systems for poorly soluble drugs - recent trends.

Riikonen J, Xu W, Lehto VP. Riikonen J, et al. Among authors: lehto vp. Int J Pharm. 2018 Jan 30;536(1):178-186. doi: 10.1016/j.ijpharm.2017.11.054. Epub 2017 Nov 26. Int J Pharm. 2018. PMID: 29183856 Review.

2

Effects of carriers and storage of formulation on the lung deposition of a hydrophobic and hydrophilic drug from a DPI.

Harjunen P, Lankinen T, Salonen H, Lehto VP, Järvinen K. Harjunen P, et al. Among authors: lehto vp. Int J Pharm. 2003 Sep 16;263(1-2):151-63. doi: 10.1016/s0378-5173(03)00357-0. Int J Pharm. 2003. PMID: 12954190

3

Moisture transfer into medicament chambers equipped with a double-barrier-desiccant system.

Lehto VP, Lankinen T. Lehto VP, et al. Int J Pharm. 2004 May 4;275(1-2):155-64. doi: 10.1016/j.ijpharm.2004.01.026. Int J Pharm. 2004. PMID: 15081146

4

Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles.

Laaksonen T, Santos H, Vihola H, Salonen J, Riikonen J, Heikkilä T, Peltonen L, Kumar N, Murzin DY, Lehto VP, Hirvonen J. Laaksonen T, et al. Among authors: lehto vp. Chem Res Toxicol. 2007 Dec;20(12):1913-8. doi: 10.1021/tx700326b. Epub 2007 Nov 9. Chem Res Toxicol. 2007. PMID: 17990852

5

Intraorally fast-dissolving particles of a poorly soluble drug: preparation and in vitro characterization.

Laitinen R, Suihko E, Toukola K, Björkqvist M, Riikonen J, Lehto VP, Järvinen K, Ketolainen J. Laitinen R, et al. Among authors: lehto vp. Eur J Pharm Biopharm. 2009 Feb;71(2):271-81. doi: 10.1016/j.ejpb.2008.09.001. Epub 2008 Sep 12. Eur J Pharm Biopharm. 2009. PMID: 18824096

6

In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles.

Kilpeläinen M, Riikonen J, Vlasova MA, Huotari A, Lehto VP, Salonen J, Herzig KH, Järvinen K. Kilpeläinen M, et al. Among authors: lehto vp. J Control Release. 2009 Jul 20;137(2):166-70. doi: 10.1016/j.jconrel.2009.03.017. Epub 2009 Apr 2. J Control Release. 2009. PMID: 19345247

7

Determination of the physical state of drug molecules in mesoporous silicon with different surface chemistries.

Riikonen J, Mäkilä E, Salonen J, Lehto VP. Riikonen J, et al. Among authors: lehto vp. Langmuir. 2009 Jun 2;25(11):6137-42. doi: 10.1021/la804055s. Langmuir. 2009. PMID: 19466777

8

Development of a highly controlled gas-phase nanoparticle generator for inhalation exposure studies.

Miettinen M, Riikonen J, Tapper U, Backman U, Joutsensaari J, Auvinen A, Lehto VP, Jokiniemi J. Miettinen M, et al. Among authors: lehto vp. Hum Exp Toxicol. 2009 Jun;28(6-7):413-9. doi: 10.1177/0960327109105155. Hum Exp Toxicol. 2009. PMID: 19755454

9

Perphenazine solid dispersions for orally fast-disintegrating tablets: physical stability and formulation.

Laitinen R, Suihko E, Bjorkqvist M, Riikonen J, Lehto VP, Jarvinen K, Ketolainen J. Laitinen R, et al. Among authors: lehto vp. Drug Dev Ind Pharm. 2010 May;36(5):601-13. doi: 10.3109/03639040903386690. Drug Dev Ind Pharm. 2010. PMID: 19954406

10

In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size.

Santos HA, Riikonen J, Salonen J, Mäkilä E, Heikkilä T, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J. Santos HA, et al. Among authors: lehto vp. Acta Biomater. 2010 Jul;6(7):2721-31. doi: 10.1016/j.actbio.2009.12.043. Epub 2009 Dec 29. Acta Biomater. 2010. PMID: 20036766

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

361 results

Search Page